Market ExpansionManagement's expansion efforts, such as increasing the sales force and support teams, have led to rising patient demand and market share for Lumryz.
Regulatory ApprovalAvadel Pharmaceuticals announced that LUMRYZ (sodium oxybate extended-release) has received Orphan Drug Designation (ODD) from the FDA for the treatment of idiopathic hypersomnia (IH).
Sales GrowthAvadel Pharmaceuticals announced an increase in expected patient numbers and revenue for their product Lumryz, signaling strong future growth.